Appointments: Novartis And GSK Fill Key R&D Roles, Celgene Board Changes And Others
Executive Summary
This week's announcements include Novartis's replacement for Vas Narasimhan as head of global development, GlaxoSmithKline's new head of worldwide business development for pharmaceuticals research & development, new board members at Celgene, an interim CEO at Nordic Nanovector, and changes at Vectura, PureTech Health and Exicure.
You may also be interested in...
Pipeline Watch: 11 Approvals And Eight Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Five Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: AVEO Pharmaceuticals, Everest Medicines and More
Recent executive changes in the industry include C-suite changes at Aveo Pharmaceuticals and Scandion Oncology. Meanwhile, new directors were appointed at Akston Biosciences and Everest Medicines.